- Home
- SIF vs NXTC Comparison
SIF vs NXTC Comparison
Compare SIF & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIF
- NXTC
- Stock Information
- Founded
- SIF 1913
- NXTC 2015
- Country
- SIF United States
- NXTC United States
- Employees
- SIF N/A
- NXTC N/A
- Industry
- SIF Office Equipment/Supplies/Services
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- SIF Industrials
- NXTC Health Care
- Exchange
- SIF Nasdaq
- NXTC Nasdaq
- Market Cap
- SIF 22.6M
- NXTC 23.0M
- IPO Year
- SIF N/A
- NXTC 2019
- Fundamental
- Price
- SIF $3.65
- NXTC $0.78
- Analyst Decision
- SIF
- NXTC Strong Buy
- Analyst Count
- SIF 0
- NXTC 2
- Target Price
- SIF N/A
- NXTC $4.00
- AVG Volume (30 Days)
- SIF 4.7K
- NXTC 117.3K
- Earning Date
- SIF 02-12-2025
- NXTC 03-20-2025
- Dividend Yield
- SIF N/A
- NXTC N/A
- EPS Growth
- SIF N/A
- NXTC N/A
- EPS
- SIF N/A
- NXTC N/A
- Revenue
- SIF $79,633,000.00
- NXTC N/A
- Revenue This Year
- SIF N/A
- NXTC N/A
- Revenue Next Year
- SIF N/A
- NXTC N/A
- P/E Ratio
- SIF N/A
- NXTC N/A
- Revenue Growth
- SIF 20.53
- NXTC N/A
- 52 Week Low
- SIF $2.90
- NXTC $0.76
- 52 Week High
- SIF $5.96
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- SIF 50.40
- NXTC 39.76
- Support Level
- SIF $3.57
- NXTC $0.76
- Resistance Level
- SIF $3.89
- NXTC $0.90
- Average True Range (ATR)
- SIF 0.12
- NXTC 0.06
- MACD
- SIF 0.02
- NXTC 0.01
- Stochastic Oscillator
- SIF 53.66
- NXTC 19.58
About SIF SIFCO Industries Inc.
SIFCO Industries Inc is engaged in the production of forgings and machined components for the Aerospace and Energy, Defense and Commercial Space markets. Its processes and services include forging, heat-treating and machining. It serves original equipment manufacturers (OEM) as well as aftermarket customers. Its products are made of steel, stainless steel, titanium and aluminium and include OEM and aftermarket components for aircraft and industrial gas turbine engines, steam turbine blades, structural airframe components, aircraft landing gear components, aircraft wheels and brakes, critical rotating components for helicopters and industrial products. Substantial revenue is derived from North America as well as operates in Europe.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.